CHA Vaccine Institute Co. Ltd.
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in p… Read more
CHA Vaccine Institute Co. Ltd. (261780) - Net Assets
Latest net assets as of September 2025: ₩17.56 Billion KRW
Based on the latest financial reports, CHA Vaccine Institute Co. Ltd. (261780) has net assets worth ₩17.56 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩39.82 Billion) and total liabilities (₩22.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩17.56 Billion |
| % of Total Assets | 44.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1662.37% |
| 10-Year Change | N/A |
| Growth Volatility | 1051.78 |
CHA Vaccine Institute Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how CHA Vaccine Institute Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CHA Vaccine Institute Co. Ltd. (2019–2024)
The table below shows the annual net assets of CHA Vaccine Institute Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩27.72 Billion | -21.73% |
| 2023-12-31 | ₩35.42 Billion | +6.15% |
| 2022-12-31 | ₩33.37 Billion | -15.78% |
| 2021-12-31 | ₩39.61 Billion | +2418.42% |
| 2020-12-31 | ₩1.57 Billion | +117.82% |
| 2019-12-31 | ₩-8.83 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CHA Vaccine Institute Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4377154528000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩13.41 Billion | 48.38% |
| Other Components | ₩80.23 Billion | 289.41% |
| Total Equity | ₩27.72 Billion | 100.00% |
CHA Vaccine Institute Co. Ltd. Competitors by Market Cap
The table below lists competitors of CHA Vaccine Institute Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
$34.15 Million |
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
$34.15 Million |
|
Ray Co. Ltd
KQ:228670
|
$34.15 Million |
|
Jaanh CosmeticsInc.
KQ:219550
|
$34.16 Million |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
$34.13 Million |
|
ONDE S.A. ZY -02
F:0XF
|
$34.11 Million |
|
Singapore Shipping Corporation Limited
F:W1M
|
$34.09 Million |
|
Sewoon Medical Co. Ltd
KQ:100700
|
$34.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHA Vaccine Institute Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,416,951,840 to 27,722,306,690, a change of -7,694,645,150 (-21.7%).
- Net loss of 10,138,367,700 reduced equity.
- Share repurchases of 199,899,540 reduced equity.
- New share issuances of 199,899,540 increased equity.
- Other factors increased equity by 2,443,722,550.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.14 Billion | -36.57% |
| Share Repurchases | ₩199.90 Million | -0.72% |
| Share Issuances | ₩199.90 Million | +0.72% |
| Other Changes | ₩2.44 Billion | +8.82% |
| Total Change | ₩- | -21.73% |
Book Value vs Market Value Analysis
This analysis compares CHA Vaccine Institute Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩-333.93 | ₩3140.00 | x |
| 2020-12-31 | ₩59.52 | ₩3140.00 | x |
| 2021-12-31 | ₩1498.91 | ₩3140.00 | x |
| 2022-12-31 | ₩1262.45 | ₩3140.00 | x |
| 2023-12-31 | ₩1324.89 | ₩3140.00 | x |
| 2024-12-31 | ₩1033.46 | ₩3140.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CHA Vaccine Institute Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2735.23%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.70x
- Recent ROE (-36.57%) is above the historical average (-84.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -2363.12% | 0.01x | 0.00x | ₩-2.10 Billion |
| 2020 | -396.71% | -8021.36% | 0.00x | 16.37x | ₩-6.40 Billion |
| 2021 | -46.50% | -3684.01% | 0.01x | 1.65x | ₩-22.38 Billion |
| 2022 | -20.13% | -3741.36% | 0.00x | 1.83x | ₩-10.05 Billion |
| 2023 | -4.94% | -594.82% | 0.01x | 1.27x | ₩-5.29 Billion |
| 2024 | -36.57% | -2735.23% | 0.01x | 1.70x | ₩-12.91 Billion |
Industry Comparison
This section compares CHA Vaccine Institute Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHA Vaccine Institute Co. Ltd. (261780) | ₩17.56 Billion | 0.00% | 1.27x | $34.14 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |